+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical review of delafloxacin: a novel anionic fluoroquinolone

Clinical review of delafloxacin: a novel anionic fluoroquinolone

Journal of Antimicrobial ChemoTherapy 73(6): 1439-1451

Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. In Phase III studies, delafloxacin had similar outcomes to comparator regimens for treatment of ABSSSIs, and was well tolerated overall. Similar to other FQs, delafloxacin is available in both intravenous and oral formulations, but differs in that delafloxacin exerts a minimal effect on cytochrome P450 enzymes and on the corrected QT interval. This novel FQ has the potential to be utilized across a wide variety of clinical settings; however, post-marketing surveillance and long-term safety and resistance data will be essential to identify optimal use scenarios.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054895096

Download citation: RISBibTeXText

PMID: 29425340

DOI: 10.1093/jac/dkx543

Related references

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clinical Infectious Diseases 68(Supplement_3): S213, 2019

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone. Journal of Clinical Microbiology 56(8):, 2018

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiology 10(7): 1111-1123, 2015

Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrobial Agents and ChemoTherapy 58(11): 6385-6397, 2014

In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance. Antimicrobial Agents and ChemoTherapy 60(5): 3106-3111, 2016

What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone. PharmacoTherapy 38(1): 108-121, 2018

Delafloxacin (Baxdela)--a new fluoroquinolone antibiotic. Medical Letter on Drugs and Therapeutics 60(1543): 49-51, 2018

Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clinical Infectious Diseases 68(6): 1058-1062, 2019

Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiology 13: 1081-1094, 2018

Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Review of Anti-Infective Therapy 16(7): 523-530, 2018

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. Infectious Diseases and Therapy 7(2): 197-217, 2018

Baxdela TM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections. P and T 43(11): 662-666, 2018

Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin. European Journal of Drug Metabolism and Pharmacokinetics 44(3): 305-317, 2019

Fluoroquinolone photosensitization A review of clinical and laboratory studies. Photochemistry and Photobiology 62(6): 954-958, 1995

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. Journal of Clinical Pharmacology 57(3): 328-335, 2017